muramylnac-ala-isogln-lys-tripeptide has been researched along with Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baseler, MW; Urba, WJ | 1 |
1 review(s) available for muramylnac-ala-isogln-lys-tripeptide and Neoplasms
| Article | Year |
|---|---|
Immunological monitoring and clinical trials of biological response modifiers.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-alpha; Interferon-beta; Interferon-gamma; Interleukin-2; Monitoring, Immunologic; Neoplasms; Tumor Necrosis Factor-alpha | 1991 |